

Company report

28.2.2024 08:45



Lucas Mattsson +46 731589485 lucas.mattsson@inderes.com





Good potential but challenging valuation

The Q4 figures offered no major surprises but were slightly below our estimates in absolute terms. However, OptiCept announced a small directed share issue to its partner within solid foods, FPS Food Process Solutions, which will increase the cash position by approximately 10.3 MSEK before issuance costs. While we view FPS's investment in OptiCept positively, as it reduces the financing risk somewhat and indicates confidence in the successful commercialization of the technology, we believe that the fundamental-based valuation is too high, exceeding our fair value range of SEK 1.5-2.7 per share. Additionally, we anticipate the need for further financing during the year, leading us to perceive the risks as too great to rely on the potential. Thus, we reiterate our target price of SEK 2.2 per share but adjust our recommendation to Sell (Reduce), due to the recent increase in the share price which we find unjustified.

Negative revenue growth but reduced costs

OptiCept's Q4 revenue decreased by -47% to 0.9 MSEK, lower than our estimate of 1.9 MSEK. However, the decline in absolute terms was relatively modest. This decrease from Q4'22 was primarily due to significantly fewer machine parts being billed during the quarter. Despite heightened activity related to OliveCept installations, OptiCept continued to implement measures to reduce costs, which showed a positive effect during the quarter; the operating loss (EBIT adj.) decreased to -23.1 MSEK (Q4'22: -30 MSEK).

Revised estimates reflecting shifted focus

Due to factors such as a weak olive oil season, climate change impacts, and economic sluggishness, potential OliveCept customers are deferring orders until grant approvals are secured, leading to our lower revenue expectations for OliveCept in the FoodTech sector. However, OptiCept's strategic shift towards solid foods, coupled with a significant order from FPS, mitigates some of the impact on sales figures. Consequently, while we anticipate a modest overall change in sales, we maintain our optimistic outlook for significant growth, aiming to fulfill nearly the entire 28 MSEK order book.

Regarding profitability, we have made minor adjustments to our estimates, mainly due to foreseeing slightly lower aftermarket revenue. Despite these adjustments, the changes in absolute figures remain minimal, and <u>our recent</u> extensive report provides a comprehensive perspective on our estimates.

Short-term risk/reward ratio in the red, but long-term positive outlook persists

Our estimates for OptiCept's sales-based multiples for 2024 are high (2024e: EV/S 6x) and only 2026 year's EV/S multiple of ~2x looks more neutral, but the estimate risk is also higher in this scenario since the time horizon is longer. In our DCF model, under the neutral scenario, we project a value of SEK 2.4 per share. However, to reach this value, a funding gap exists owing to the estimated negative cash flows relative to current cash balances. Our estimates suggest that the company will require additional financing in the range of 50-60 MSEK. As it seems now, the market currently price in that OptiCept will reach its target of positive EBITDA and thus revenue levels of 85-90 MSEK, which we are not currently confident about based on the company's order backlog and track record. However, if the company achieves these levels and continues to grow thereafter, the current valuation could offer a solid expected return.

Recommendation




Key indicators

	2023	2024e	2025e	2026e
Revenue	9.1	26.7	65.6	99.5
growth-%	-13%	191%	146%	52%
EBIT adj.	-73.6	-42.0	-36.5	-16.7
EBIT-% adj.	-804.8 %	-157.5 %	-55.5 %	-16.8 %
Net Income	-80.4	-51.0	-43.5	-23.7
EPS (adj.)	-2.00	-1.08	-0.92	-0.50
P/E (adj.)	neg.	neg.	neg.	neg.
P/B	0.4	0.4	0.5	0.5
Dividend yield-%	0.0 %	0.0 %	0.0 %	0.0 %
EV/EBIT (adj.)	neg.	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.	>100
EV/S	17.5	5.8	3.0	2.2

Source: Inderes

Guidance (OptiCept p

(OptiCept provides no guidance)



M Value drivers

- Proven technology to extend the shelf life and enhance the quality of food and plants
- Growing markets driven by significant trends
 such as sustainability
- Optionality and scalable business model
- Short payback period for customers lowers the barrier to invest in the technology

Risk factors

- Challenges of breaking into conservative markets raise the risk level
- Growth strategy eats away on cash assets and requires additional funding
- Competing solutions and emerging rivals
- The business model proves ineffective and demand is weak

Valuation	2024 e	2025 e	2026e
Share price	2.80	2.80	2.80
Number of shares, millions	47.1	47.1	47.1
Market cap	132	132	132
EV	155	194	217
P/E (adj.)	neg.	neg.	neg.
P/E	neg.	neg.	neg.
P/B	0.4	0.5	0.5
P/S	5.0	2.0	1.3
EV/Sales	5.8	3.0	2.2
EV/EBITDA	neg.	neg.	>100
EV/EBIT (adj.)	neg.	neg.	neg.
Payout ratio (%)	0.0 %	0.0 %	0.0 %
Dividend yield-%	0.0 %	0.0 %	0.0 %

Still high burn rate but short-term financing secured

Sales somewhat weaker than expected

OptiCept's Q4 revenue decreased by -47% to 0.9 MSEK, below our estimates of 1.9 MSEK. However, in absolute terms, the decline was relatively modest. This decrease compared to Q4'22 was primarily due to significantly fewer machine parts being billed during the quarter. Nevertheless, the reduction in machine part sales does not impact the bottom line, as the company repurchases finished machines from the supplier, affecting costs instead.

A better perspective on revenue development is, in our view, provided by examining sales growth in the different business areas. During the quarter, OptiCept showed good growth in both FoodTech and PlantTech, with increases of 31% and 175%, respectively. However, it's important to note that these figures are based on small volumes.

Efforts to cut costs resulted in a reduction in operating losses

OptiCept has implemented measures to reduce external costs and personnel expenses, which began to show results in Q3'23. However, due to heightened activity related to OliveCept installations, the operating profit (EBIT adj.) fell below our expectations, amounting to -23.1 MSEK. Similarly, EPS (adj.) was lower than anticipated, primarily due to lower revenue, higherthan-expected fixed costs, and interest expenses.

OptiCept also reported weaker-than-expected cash flow, primarily attributable to lower operating profits than estimated. Despite the directed issue and redemption of warrants during the quarter, which somewhat helped to offset the weak cash flow, the company's net cash position at the end of the period stood at 14.2 MSEK.

Short-term financing secured

OptiCept announced a small directed share issue of approximately 4.9 million shares (resulting in a 10.5% dilution) to FPS Food Process Solutions at a price of 2.08 SEK per share. This will increase the cash position by approximately 10.3 MSEK, before issuance costs. The funds will primarily support the company's ongoing commercial expansion efforts.

We view FPS's investment in OptiCept positively, indicating confidence in the technology and aligning interests in successfully commercializing it for solid foods. While this move reduces the financing risk somewhat, additional financing may still be necessary during the year, potentially exposing investors to a dilution risk, based on our estimates. Given the current burn rate of approximately 5 MSEK a month, as well as the cash position of around SEK 24 million, including the directed issue, the company will be financed until around Q2/Q3'24.

Estimates	Q4'22	Q4'23	Q4'23e	Q4'23e	Consensus		Difference (%)	2023
MSEK/SEK	Comparison	Actualized	Inderes	Consensus	Low	High	Act. vs. inderes	Actual
Revenue	1.6	0.9	1.9				-55%	9.1
EBITDA	-29.9	-18.0	-13.5				34%	-53.6
EBIT (adj.)	-30.0	-23.1	-18.1				28%	-73.6
EBIT	-36.8	-23.1	-18.1				28%	-73.6
PTP	-41.5	-20.2	-20.1				1%	-78.8
EPS (adj.)	-1.73	-0.57	-0.50				14%	-2.48
Revenue growth-%	734 %	-47 %	18 %				-64.5 pp	-13 %

We adjust our estimates slightly reflecting changed focus

Estimate changes

- Due to a weak olive oil season characterized by poor harvests, climate change and a sluggish economy, potential customers are deferring orders until grants are approved. Consequently, we anticipate lower revenue for OliveCept within the FoodTech sector. However, with OptiCept's reprioritization efforts, reallocating investment from olive oil to solid foods as a priority area and securing a first order from FPS, we have shifted our focus towards solid foods in our FoodTech segment estimates. This helps to somewhat offset the negative impact of expected lower sales from OliveCept, resulting in a modest overall change in sales figures.
- We have made only minor adjustments to our profitability estimates, primarily due to anticipating slightly lower aftermarket revenue, which we believe will contribute to a higher margin. However, the changes in absolute figures are minimal.
- We maintain our long-term growth estimates and our confidence in the company's ability to
 experience substantial growth and increased profitability in the coming years. However, our
 estimates are contingent upon various uncertain assumptions, the accuracy of which will only be
 realized over time. These assumptions include both revenue and required growth investments, as
 well as the cost structure of the business.

Estimate revisions	2023	2023	Change	2024 e	2024e	Change	2025 e	2025e	Change
MSEK/SEK	Inderes	Actualized	%	Old	New	%	Old	New	%
Revenue	10.2	9.1	-10%	27.3	26.7	-3%	67.5	65.6	-3%
EBITDA	-49.1	-53.6	9%	-18.3	-20.4	12%	-15.5	-16.1	4%
EBIT (exc. NRIs)	-68.6	-73.6	7%	-39.9	-42.0	5%	-35.3	-36.5	3%
EBIT	-68.6	-73.6	7%	-39.9	-42.0	5%	-35.3	-36.5	3%
PTP	-78.6	-78.8	0%	-48.9	-51.0	4%	-42.3	-43.5	3%
EPS (excl. NRIs)	-1.96	-2.00	2%	-1.07	-1.08	2%	-0.92	-0.92	0%
DPS	0.00	0.00		0.00	0.00		0.00	0.00	

Risk profile of the business model



Assessment of OptiCept's overall business risk

The industry is currently in its early stages of development, undergoing continuous and rapid changes.

OptiCept's technology is relatively new, particularly in the field of PlantTech. Despite its proven effectiveness, commercialization is still in its early stages.

The market has strong demand drivers, but general economic development affects customers' R&D projects.

Sales are just beginning, thus no permanent revenue base. In the long term, revenue is expected to be partly recurring, as well as distributed among multiple customers and geographic areas.

Cost structure is mostly fixed, but we estimate that gross margins are relatively high in a more mature stage.

Strategy aims at strong growth at the expense of short-term result. High fixed costs depress the result in the short term.

Outsourced production minimizes tied-up capital, yet initial capital is tied up as machines are deployed for customer evaluations, yielding limited cash flow.

Cash collected through debt and equity issues somewhat mitigates the loss-making phase in the growth stage. However, slower than expected growth may necessitate additional financing.

Valuation

Challenging valuation in the short term

OptiCept's profitability is clearly negative due to front-loaded growth investments. Consequently, we use sales-based multiples, specifically the EV/S ratio, in this case. However, considering OptiCept's earlystage commercialization, sales-based multiples do not offer support for the current and upcoming years. The EV/S ratio for OptiCept in 2024 stands at 6x, a level we view as very high at this stage, despite the company's substantial market potential and a scalable business model. Furthermore, OptiCept's 2024 sales multiple is approximately 400% higher than that of its peer group comprising similar-stage companies. However, forming a relevant peer group for OptiCept at its current developmental stage poses challenges. The valuation picture looks somewhat more attractive looking into 2026 (EV/S 2x) than in the short term, but the estimate risk is also higher in this scenario since the time horizon is longer.

Number of shares is likely to increase

We also use a DCF model with different scenarios in the valuation. We point out, however, that our DCF model is based on the company's current number of shares, although in all our DCF scenarios we expect that the company will need additional equity financing to carry out the growth investments required by our estimates (i.e., we expect the number of shares to increase).

In the optimistic scenario, we estimate OptiCept to achieve its 2024 targets of positive EBITDA and 85-90 MSEK in revenue. Long-term revenue is anticipated to be approximately 50% higher, with EBIT 75% higher by 2037 compared to the neutral scenario. This optimistic outlook results in value per share ranging from SEK 4.9 to 10.9, with a base case of SEK 6.6 per share. Achieving this scenario necessitates significant commercial breakthroughs, market leadership, and high-volume sales in key business areas.

Conversely, in the pessimistic scenario, OptiCept's long-term revenue is reduced by about 20%, and EBIT by 35%. This scenario results in a valuation range from SEK 0.4 to 2.5 per share, with a base case of SEK 1.0 per share. Market creation is expected to be slower, with limited market share despite investments. Additionally, this scenario may require more capital than the neutral scenario.


The neutral scenario is in line with our current estimates. The equity value of OptiCept under our DCF model in the neutral scenario is 114 MSEK or SEK 2.4 per share. We feel that in light of the neutral scenario, OptiCept's share is currently quite expensive given the high required return, tolerance of the model and the likely growth pressure in the number of shares.

Significant potential, yet facing short-term financing challenges

In an optimistic scenario, the valuation could provide a solid expected return even with current valuations. We do, however, believe that investors should demand a considerable return to bear the risk and uncertainty. In addition, we estimate that the company will need further financing, so we feel that the risks are too great to rely on the potential. Thus, we reiterate our target price of SEK 2.2 per share but change our recommendation to Sell (Reduce).

Valuation	2024e	2025 e	2026e
Share price	2.80	2.80	2.80
Number of shares, millions	47.1	47.1	47.1
Market cap	132	132	132
EV	155	194	217
P/E (adj.)	neg.	neg.	neg.
P/E	neg.	neg.	neg.
P/FCF	neg.	neg.	neg.
P/B	0.4	0.5	0.5
P/S	5.0	2.0	1.3
EV/Sales	5.8	3.0	2.2
EV/EBITDA	neg.	neg.	>100
EV/EBIT (adj.)	neg.	neg.	neg.
Payout ratio (%)	0.0 %	0.0 %	0.0 %
Dividend yield-%	0.0 %	0.0 %	0.0 %
Courses Inderes			

Source: Inderes



Sensitivity of the DCF value to the WACC

SEK per share, WACC-%

Valuation table

Valuation	2019	2020	2021	2022	2023	2024 e	2025 e	2026 e	2027 e
Share price	23.8	55.4	87.9	10.4	3.89	2.80	2.80	2.80	2.80
Number of shares, millions	11.1	11.6	16.3	19.9	40.2	47.1	47.1	47.1	47.1
Market cap	263	643	1435	207	156	132	132	132	132
EV	250	622	1373	144	160	155	194	217	240
P/E (adj.)	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.
P/E	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.
P/FCF	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.
P/B	11.6	18.4	3.5	0.5	0.4	0.4	0.5	0.5	0.6
P/S	75.6	>100	>100	19.7	17.1	5.0	2.0	1.3	0.9
EV/Sales	71.7	>100	>100	13.7	17.5	5.8	3.0	2.2	1.7
EV/EBITDA	neg.	neg.	neg.	neg.	neg.	neg.	neg.	>100	36.6
EV/EBIT (adj.)	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.
Payout ratio (%)	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Dividend yield-%	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %

Peer group valuation

Peer group valuation	Market cap	EV	E\	EV/S		Sales growth		Dividend yield-%	
Company	MEUR	MEUR	2024e	2025e	2024e	2025e	2024e	2025e	2024e
Merus Power Oyj	37	38	1.2	1.0	7%	26%		1.7	3.1
Enwave Corp	19	17	0.9	0.4		120%			
Nederman Holding	579	696	1.3	1.2		5%	2.2	2.1	2.5
Gea Group	6435	6225	1.1	1.1	2%	3%	2.9	3.2	2.4
OptiCept (Inderes)	12	14	5.8	3.0	191 %	146 %	0.0	0.0	0.4
Average			1.1	0.9	5%	39%	2.6	2.3	2.7
Median			1.2	1.0	5%	16 %	2.6	2.1	2.5
Diff-% to median			395 %	186 %	4155%	844 %	-100%	- 100 %	-83 %

Source: Refinitiv / Inderes

Income statement

Income statement	2021	2022	2023	Q1'24e	Q2'24e	Q3'24e	Q4'24e	2024e	2025 e	2026e	2027 e
Revenue	4.4	10.5	9.1	5.3	6.6	6.7	8.0	26.7	65.6	99.5	141
Group	4.4	10.5	9.1	5.3	6.6	6.7	8.0	26.7	65.6	99.5	141
EBITDA	-36.7	-77.3	-53.6	-4.3	-4.6	-5.6	-5.8	-20.4	-16.1	1.4	6.5
Depreciation	-10.4	-19.2	-20.0	-5.4	-5.4	-5.4	-5.4	-21.6	-20.4	-18.1	-16.5
EBIT (excl. NRI)	-47.1	-89.7	-73.6	-9.7	-10.0	-11.0	-11.2	-42.0	-36.5	-16.7	-10.0
EBIT	-47.1	-96.5	-73.6	-9.7	-10.0	-11.0	-11.2	-42.0	-36.5	-16.7	-10.0
Group	-47.1	-96.5	-73.6	-9.7	-10.0	-11.0	-11.2	-42.0	-36.5	-16.7	-10.0
Share of profits in assoc. compan.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net financial items	-0.2	-5.8	-5.2	-3.0	-2.0	-2.0	-2.0	-9.0	-7.0	-7.0	-7.0
РТР	-47.3	-102.3	-78.8	-12.7	-12.0	-13.0	-13.2	-51.0	-43.5	-23.7	-17.0
Taxes	0.0	2.2	-1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net earnings	-47.0	-100.1	-80.4	-12.7	-12.0	-13.0	-13.2	-51.0	-43.5	-23.7	-17.0
EPS (adj.)	-2.88	-4.68	-2.00	-0.27	-0.26	-0.27	-0.28	-1.08	-0.92	-0.50	-0.36
EPS (rep.)	-2.88	-5.02	-2.00	-0.27	-0.26	-0.27	-0.28	-1.08	-0.92	-0.50	-0.36
Key figures	2021	2022	2023	Q1'24e	Q2'24e	Q3'24e	Q4'24e	2024e	2025 e	2026e	2027 e
Revenue growth-%	1515.8 %	136.5 %	-12.9 %	6.9 %	197.8 %	524.4 %	820.2 %	191.5 %	146.3 %	51.6 %	41.3 %
Adjusted EBIT growth-%		90.4 %	-18.0 %	-44.8 %	-33.6 %	-38.3 %	-51.3 %	-43.0 %	-13.1 %	-54.1 %	-40.2 %
EBITDA-%	-826.3 %	-736.2 %	-586.2 %	-81.6 %	-70.3 %	-82.4 %	-73.0 %	-76.4 %	-24.5 %	1.4 %	4.7 %
Adjusted EBIT-%	-1061.4 %	-854.5 %	-804.8 %	-182.9 %	-152.3 %	-162.5 %	-140.5 %	-157.5 %	-55.5 %	-16.8 %	-7.1 %
Net earnings-%	-1059.1 %	-951.2 %	-879.3 %	-239.1 %	-182.7 %	-192.2 %	-165.5 %	-191.2 %	-66.2 %	-23.8 %	-12.1 %

Balance sheet


Assets	2022	2023	2024 e	2025 e	2026e
Non-current assets	332	325	321	314	311
Goodwill	257	257	257	257	257
Intangible assets	68.7	64.4	61.0	53.5	48.4
Tangible assets	6.4	3.3	2.1	3.3	5.3
Associated companies	0.0	0.0	0.0	0.0	0.0
Other investments	0.0	0.0	0.0	0.0	0.0
Other non-current assets	0.2	0.2	0.2	0.2	0.2
Deferred tax assets	0.0	0.0	0.0	0.0	0.0
Current assets	141	62.1	46.3	62.7	73.3
Inventories	30.8	43.4	32.0	36.1	39.8
Other current assets	8.6	3.6	3.6	3.6	3.6
Receivables	6.7	1.0	8.0	16.4	19.9
Cash and equivalents	94.7	14.1	2.7	6.6	9.9
Balance sheet total	473	387	367	377	384

Liabilities & equity	2022	2023	2024e	2025 e	2026 e
Equity	396	350	315	271	247
Share capital	2.7	3.6	4.2	4.2	4.2
Retained earnings	-56.3	-271.4	-322.4	-365.9	-389.6
Hybrid bonds	0.0	0.0	0.0	0.0	0.0
Revaluation reserve	0.0	0.0	0.0	0.0	0.0
Other equity	450	618	633	633	633
Minorities	0.1	0.0	0.0	0.0	0.0
Non-current liabilities	26.4	21.7	16.7	40.9	63.3
Deferred tax liabilities	0.0	1.6	1.6	1.6	1.6
Provisions	0.0	0.3	0.3	0.3	0.3
Interest bearing debt	1.9	0.5	10.3	34.4	56.9
Convertibles	20.0	14.8	0.0	0.0	0.0
Other long term liabilities	4.5	4.5	4.5	4.5	4.5
Current liabilities	50.8	15.3	35.5	64.9	73.6
Interest bearing debt	10.1	3.0	15.4	34.4	37.9
Payables	21.8	1.6	9.3	19.7	24.9
Other current liabilities	18.9	10.7	10.7	10.7	10.7
Balance sheet total	473	387	367	377	384


DCF calculation


DCF model	2023	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	2037e	2038e	TERM
Revenue growth-%	-12.9 %	191.5 %	146.3 %	51.6 %	41.3 %	25.0 %	27.0 %	16.0 %	12.0 %	11.0 %	8.0 %	6.0 %	5.0 %	3.0 %	3.0 %	2.5 %	2.5 %
EBIT-%	-804.8 %	-157.5 %	-55.5 %	-16.8 %	-7.1 %	3.0 %	10.0 %	14.0 %	16.0 %	18.0 %	20.0 %	20.0 %	20.0 %	18.0 %	18.0 %	18.0 %	18.0 %
EBIT (operating profit)	-73.6	-42.0	-36.5	-16.7	-10.0	5.3	22.3	36.2	46.4	57.9	69.5	73.7	77.3	71.7	73.9	75.7	
+ Depreciation	20.0	21.6	20.4	18.1	16.5	15.8	15.4	14.4	14.6	14.8	15.0	15.3	15.5	15.7	15.8	14.9	
- Paid taxes	0.0	0.0	0.0	0.0	0.0	0.2	-3.6	-6.6	-8.7	-11.3	-13.9	-14.8	-15.5	-14.4	-14.8	-15.6	
- Tax, financial expenses	0.1	0.0	0.0	0.0	0.0	-1.2	-1.0	-0.8	-0.8	-0.6	-0.4	-0.4	-0.4	-0.4	-0.4	0.0	
+ Tax, financial income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Change in working capital	-30.3	12.2	-2.2	-2.0	-7.3	-1.8	-2.9	0.3	0.2	-1.9	-3.9	-3.1	-2.8	-1.7	-1.8	-1.5	
Operating cash flow	-83.9	-8.2	-18.2	-0.6	-0.8	18.2	30.2	43.4	51.6	58.9	66.4	70.6	74.1	70.9	72.6	73.4	
+ Change in other long-term liabilities	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Gross CAPEX	-12.7	-17.0	-14.0	-15.0	-15.0	-15.2	-15.4	-15.6	-15.8	-16.0	-16.2	-16.4	-16.6	-16.0	-16.0	-16.0	
Free operating cash flow	-96.2	-25.2	-32.2	-15.6	-15.8	3.0	14.8	27.8	35.8	42.9	50.2	54.2	57.5	54.9	56.6	57.4	
+/- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
FCFF	-96.2	-25.2	-32.2	-15.6	-15.8	3.0	14.8	27.8	35.8	42.9	50.2	54.2	57.5	54.9	56.6	57.4	513
Discounted FCFF		-22.5	-25.3	-10.8	-9.6	1.6	6.9	11.4	12.8	13.5	13.8	13.1	12.2	10.2	9.3	8.2	73.6
Sum of FCFF present value		118	141	166	177	187	185	178	167	154	140	127	114	101	91.1	81.8	73.6
Enterprise value DCF		118															
- Interest bearing debt		-18.3							6.	sh flow dis	tributio n						
+ Cash and cash equivalents		14.1							Cd	sii now uis	Indution						
-Minorities		0.0															
-Dividend/capital return		0.0															
Equity value DCF		114		2024e-2028	le	-56%											
Equity value DCF per share		2.42															
WACC																	
Tax-% (WACC)		20.6 %		2029e-2033	e								49%				
Target debt ratio (D/(D+E)		10.0 %															
Cost of debt		6.0 %															
Equity Beta		2.00															
Market risk premium		4.75%	2	034e- & TERI	M											107	7%
Liquidity premium		3.00%															
Risk free interest rate		2.5 %															
Cost of equity		15.0 %						202	4e-2028e	■2029e-20)33e 2 03	34e- & TERM					
Weighted average cost of capital (WACC)		14.0 %															

DCF sensitivity calculations and key assumptions in graphs




Sensitivity of DCF to changes in the terminal EBIT margin





Growth and profitability assumptions in the DCF calculation



Summary

Income statement	2021	2022	2023	2024 e	2025 e	Per share data	2021	2022	2023	2024e	2025 e
Revenue	4.4	10.5	9.1	26.7	65.6	EPS (reported)	-2.88	-5.02	-2.00	-1.08	-0.92
EBITDA	-36.7	-77.3	-53.6	-20.4	-16.1	EPS (adj.)	-2.88	-4.68	-2.00	-1.08	-0.92
EBIT	-47.1	-96.5	-73.6	-42.0	-36.5	OCF / share	-3.00	-3.49	-2.09	-0.17	-0.39
PTP	-47.3	-102.3	-78.8	-51.0	-43.5	FCF / share	-23.12	-4.16	-2.39	-0.53	-0.68
Net Income	-47.0	-99.9	-80.4	-51.0	-43.5	Book value / share	24.90	19.90	8.72	6.67	5.75
Extraordinary items	0.0	-6.8	0.0	0.0	0.0	Dividend / share	0.00	0.00	0.00	0.00	0.00
Balance sheet	2021	2022	2023	2024e	2025e	Growth and profitability	2021	2022	2023	2024 e	2025e
Balance sheet total	435.8	473.3	387.3	366.8	376.9	Revenue growth-%	1516%	136%	-13%	191 %	146 %
Equity capital	406.3	396.1	350.3	314.6	271.1	EBITDA growth-%	254%	111%	-31%	- 62 %	-21 %
Goodwill	257.2	257.2	257.2	257.2	257.2	EBIT (adj.) growth-%	297%	90%	-18%	-43%	-13%
Net debt	-61.4	-62.8	4.2	23.1	62.3	EPS (adj.) growth-%	180%	62%	-57%	-46%	-15%
						EBITDA-%	-826.3 %	-736.2 %	-586.2 %	- 76.4 %	-24.5 %
Cash flow	2021	2022	2023	2024e	2025e	EBIT (adj.)-%	-1061.4 %	-854.5 %	-804.8 %	-157.5 %	-55.5 %
EBITDA	-36.7	-77.3	-53.6	-20.4	-16.1	EBIT-%	-1061.4 %	-919.3 %	-804.8 %	-157.5 %	-55.5 %
Change in working capital	-12.2	5.8	-30.3	12.2	-2.2	ROE-%	-21.3 %	-24.9 %	-21.5 %	-15.3 %	-14.8 %
Operating cash flow	-48.9	-69.5	-83.9	-8.2	-18.2	ROI-%	-21.0 %	-23.0 %	-18.5 %	-11.8 %	-10.7 %
CAPEX	-333.3	-13.5	-12.7	-17.0	-14.0	Equity ratio	93.2 %	83.7 %	90.4 %	85.8 %	71.9 %
Free cash flow	-377.5	-82.7	-96.2	-25.2	-32.2	Gearing	-15.1 %	-15.8 %	1.2 %	7.3 %	23.0 %

Valuation multiples	2021	2022	2023	2024 e	2025e
EV/S	>100	13.7	17.5	5.8	3.0
EV/EBITDA (adj.)	neg.	neg.	neg.	neg.	neg.
EV/EBIT (adj.)	neg.	neg.	neg.	neg.	neg.
P/E (adj.)	neg.	neg.	neg.	neg.	neg.
P/B	3.5	0.5	0.4	0.4	0.5
Dividend-%	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %

Disclaimer and recommendation history

The information presented in Inderes reports is obtained from several different public sources that Inderes considers to be reliable. Inderes aims to use reliable and comprehensive information, but Inderes does not guarantee the accuracy of the presented information. Any opinions, estimates and forecasts represent the views of the authors. Inderes is not responsible for the content or accuracy of the presented information. Inderes and its employees are also not responsible for the financial outcomes of investment decisions made based on the reports or any direct or indirect damage caused by the use of the information. The information used in producing the reports may change quickly. Inderes makes no commitment to announcing any potential changes to the presented information and opinions.

The reports produced by Inderes are intended for informational use only. The reports should not be construed as offers or advice to buy, sell or subscribe investment products. Customers should also understand that past performance is not a guarantee of future results. When making investment decisions, customers must base their decisions on their own research and their estimates of the factors that influence the value of the investment and take into account their objectives and financial position and use advisors as necessary. Customers are responsible for their investment decisions and their financial outcomes.

Reports produced by Inderes may not be edited, copied or made available to others in their entirety, or in part, without Inderes' written consent. No part of this report, or the report as a whole, shall be transferred or shared in any form to the United States, Canada or Japan or the citizens of the aforementioned countries. The legislation of other countries may also lay down restrictions pertaining to the distribution of the information contained in this report. Any individuals who may be subject to such restrictions must take said restrictions into account.

Inderes issues target prices for the shares it follows. The recommendation methodology used by Inderes is based on the share's 12-month expected total shareholder return (including the share price and dividends) and takes into account Inderes' view of the risk associated with the expected returns. The recommendation policy consists of four tiers: Sell, Reduce, Accumulate and Buy. As a rule, Inderes' investment recommendations and target prices are reviewed at least 2–4 times per year in connection with the companies' interim reports, but the recommendations and target prices may also be changed at other times depending on the market conditions. The issued recommendations and target prices do not guarantee that the share price will develop in line with the estimate. Inderes primarily uses the following valuation methods in determining target prices and recommendations: Cash flow analysis (DCF), valuation multiples, peer group analysis and sum of parts analysis. The valuation methods and target price criteria used are always company-specific and they may vary significantly depending on the company and (or) industry.

Inderes' recommendation policy is based on the following distribution relative to the 12-month risk-adjusted expected total shareholder return.

Buy The 12-month risk-adjusted expected shareholder return of the share is very attractive

Accumulate The 12-month risk-adjusted expected shareholder return of the share is attractive

Reduce The 12-month risk-adjusted expected shareholder return of the share is weak

Sell The 12-month risk-adjusted expected shareholder return of the share is very weak

The assessment of the 12-month risk-adjusted expected total shareholder return based on the above-mentioned definitions is company-specific and subjective. Consequently, similar 12-month expected total shareholder returns between different shares may result in different recommendations, and the recommendations and 12-month expected total shareholder returns between different shares should not be compared with each other. The counterpart of the expected total shareholder return between different shares should not be compared with each other. The counterpart of the expected total shareholder return does not necessarily lead to positive performance when the risks are exceptionally high and, correspondingly, a low expected total shareholder return does not necessarily lead to a negative recommendation if Inderes considers the risks to be moderate.

The analysts who produce Inderes' research and Inderes employees cannot have 1) shareholdings that exceed the threshold of significant financial gain or 2) shareholdings exceeding 1% in any company subject to Inderes' research activities. Inderes Oyj can only own shares in the target companies it follows to the extent shown in the company's model portfolio investing real funds. All of Inderes Oyj's shareholdings are presented in itemised form in the model portfolio. Inderes Oyj does not have other shareholdings in the target companies analysed. The remuneration of the analysts who produce the analysis are not directly or indirectly linked to the issued recommendation or views. Inderes Oyj does not have investment bank operations.

Inderes or its partners whose customer relationships may have a financial impact on Inderes may, in their business operations, seek assignments with various issuers with respect to services provided by Inderes or its partners. Thus, Inderes may be in a direct or indirect contractual relationship with an issuer that is the subject of research activities. Inderes and its partners may provide investor relations services to issuers. The aim of such services is to improve communication between the company and the capital markets. These services include the organisation of investor events, advisory services reports.

More information about research disclaimers can be found at www.inderes.fi/research-disclaimer.

Inderes has made an agreement with the issuer and target of this report, which entails compiling a research report.

Recommendation history (>12 mo)

Date	Recommendation	Target	Share price
2024-02-02	Reduce	2.20 kr	2.51 kr
2024-02-28	Sell	2.20 kr	2.80 kr

inde res.

Inderes democratizes investor information by connecting investors and listed companies.

We help over 400 listed companies better serve investors. Our investor community is home to over 70,000 active members.

We build solutions for listed companies that enable frictionless and effective investor relations. For listed companies, we offer Commissioned Research, IR Events, AGMs, and IR Software.

Inderes is listed on the Nasdag First North growth market and operates in Finland, Sweden, Norway, and Denmark.

Inderes Oyj

Itämerentori 2 FI-00180 Helsinki, Finland +358 10 219 4690

Award-winning research at inderes.fi



THOMSON REUTERS ANALYST AWARDS







Mikael Rautanen 2014, 2016, 2017, 2019

Sauli Vilén 2012, 2016, 2018, 2019, 2020



2012, 2016, 2017, 2018, 2019, 2020



Antti Viljakainen 2014, 2015, 2016, 2018, 2019, 2020

Olli Koponen

2020



Joni Grönqvist 2019, 2020



Erkki Vesola 2018, 2020



Petri Gostowski 2020



Atte Riikola 2020

Connecting investors and listed companies.